SCHEMBL25866702

SCHEMBL25866702

COC(=O)C(C)c1cn(C(=O)OC(C)(C)C)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 4/20 0.45
MEN1 O00255 2/20 0.45
EPHX1 P07099 1/20 0.44
PIM1 P11309 1/20 0.42
MARK3 P27448 1/20 0.42
MAP4K2 Q12851 1/20 0.42
CAMK2B Q13554 1/20 0.42
PIM3 Q86V86 1/20 0.42
PIM2 Q9P1W9 1/20 0.42
ACHE P22303 1/20 0.40
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
PDE10A Q9Y233 1/20 0.40
ADAM17 P78536 1/20 0.39
HTR6 P50406 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651318 1.00 L3MBTL1 (0.53) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL17102820 0.88 KMT2A (0.57) L3MBTL1KMT2AMEN1ALDH1A1MAPT
SCHEMBL13570155 0.85 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL30619496 0.85 L3MBTL1 (0.55) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL16726928 0.84 L3MBTL1 (0.54) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL29992237 0.84 L3MBTL1 (0.49) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL29444442 0.83 HTR6 (0.40) L3MBTL1KMT2AMEN1HTR6
SCHEMBL9471393 0.83 L3MBTL1 (0.53) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL7024562 0.83 L3MBTL1 (0.53) L3MBTL1KMT2AMEN1EPHX1PIM1
SCHEMBL25309481 0.83 KMT2A (0.44) KMT2AMEN1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 US disclosed
WO-2023134608-A1 FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS 微境生物医药科技(上海)有限公司 2023-07-20 WO disclosed
WO-2023134608-A1 FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS 微境生物医药科技(上海)有限公司 2023-07-20 WO disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
CN-114555585-A HPK1 inhibitors and uses thereof 上海齐鲁锐格医药研发有限公司 2022-05-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 L3MBTL1 2092/4885KMT2A 1353/4885MEN1 3442/4885
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 L3MBTL1 2199/4885KMT2A 2256/4885MEN1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.